Screening and treatment of latent tuberculosis in a cohort of asylum seekers in Norway

Abstract

Aims: Asylum seekers are screened for tuberculosis at entry to Norway. We aimed to assess follow-up of screening results at different healthcare levels in relation to demographics, screening results and organizational factors, and how this influenced treatment of latent tuberculosis. Methods: All asylum seekers ≥18 years with a Mantoux test ≥6 mm or positive x-ray findings who arrived at the National Reception Centre from January 2005 to June 2006, were included. Data were collected from public health authorities in the municipality where the asylum seekers had moved, and from internists in case they had been referred to a specialist. Specialists are responsible for treating latent tuberculosis. Individual subjects were matched with the National Tuberculosis Register to which everybody who had started treatment for latent tuberculosis was reported. Results: Of 4,643 asylum seekers, 2,237 fulfilled the inclusion criteria. By May 2008, 30 persons had started treatment for latent TB, a median of 17 months (range 3—36) after arrival. A Mantoux test ≥15 mm on arrival was significantly associated with treatment. Demographic factors influenced follow-up in primary healthcare while screening results did not. Referral to specialist was related to screening results. Several specialists were reluctant to diagnose and treat latent tuberculosis and to treat persons without a permanent visa in particular. Conclusions: Just 1% of the study group received treatment for latent tuberculosis and with a long time delay. The reason for this may be organizational factors affecting follow-up and referral and specialists not following current guidelines.

Keywords

Immigrant immigration refugee screening tuberculosis

Get full access to this article

View all access options for this article.

References

Winje BA , Mannsåker T. , Heldal E. , Dahle UR Tuberkulose i Norge 2006 (Tuberculosis in Norway, 2006. A report from the Infectious Disease Control Register) (Norwegian). MSISrapport 2007;35.

Dahle UR , Sandven P. , Heldal E. , Caugant DA Continued low rates of transmission of Mycobacterium tuberculosis in Norway . J Clin Microbiol 2003;41(7):2968-73.

Farah MG , Tverdal A. , Selmer R. , Heldal E. , Bjune G. Tuberculosis in Norway by country of birth, 1986-1999. Int J Tuberc Lung Dis 2003;7(3):232-5.

WHO Global Health atlas [database on the Internet] 2009. http://apps.who.int/globalatlas/dataQuery/reportData.asp?rptType=1 (accessed 17 August 2009).

Johnsen NL , Steen TW , Meyer HE , Heldal E. , Skarpaas IJK , Bjune G. Cohort analysis of asylum seekers in Oslo, Norway, 1987-1995: effectiveness of screening at entry and TB incidence in subsequent years. Int J Tuberc Lung Dis 2005 ;9(1):37-42.

Broekmans JF , Migliori GB , Rieder HL , Lees J. , Ruutu P. , Loddenkemper R. , et al. European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J 2002;19:765-75.

Forskrift om tuberkulosekontroll (Norwegian)[Regulations on control of tuberculosis] In: Services MoHaC , editor; 2002. (http://www.lovdata.no/cgi-wift/ldles?doc=/sf/sf/sf-20020621-0567.html ) (accessed 26 October 2009).

Nasjonalt Folkehelseinstitutt. Forebygging og kontroll av tuberkulose, en veileder (Norwegian)[Guidelines for prevention and control of tuberculosis], 7th edn. Oslo: Nasjonalt Folkehelseinstitutt ; 2002.

Harstad I. , Heldal E. , Steinshamn SL , Garasen H. , Jacobsen GW Tuberculosis screening and follow-up of asylum seekers in Norway. A cohort study. BMC Public Health 2009;9(1):141.

10.

Winje BA , Oftung F. , Korsvold GO , Mannsåker T. , Jeppesen AS , Harstad I. , et al. Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERON TB Gold with tuberculin skin test. BMC Infectious Diseases [serial on the Internet]. 2008;8:65.

11.

Breuss E. , Helbling P. , Altpeter E. , Zellweger J-P . Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly 2002;132:197-200.

12.

von Reyn CF , Horsburgh CR , Olivier KN , Barnes PF , Waddell R. , Warren C. , et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001;5(12):1122-8.

13.

Kang YA , Lee HW , Yoon HI , Cho B. , Han SK , Shim YS , et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293(22):2756-61.

14.

Prophylaxis IUATCo. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60(4):555-64.

15.

Van Burg JL , Verver S. , Borgdorff MW The epidemiology of tuberculosis among asylum seekers in the Netherlands: implication for screening . Int J Tuberc Lung Dis 2003;7(2):139-44.

16.

Yew WW , Leung CC Antituberculosis drugs and hepatotoxicity . Respirology 2006;11(6):699-707.

17.

Richards B. , Kozak R. , Brassard P. , Menzies D. , Schwartzman K. Tuberculosis surveillance among new immigrants in Montreal. Int J Tuberc Lung Dis 2005;9(8):858-64.